IGF2BP3 Antibody (C-11): sc-365641
- IGF2BP3 Antibody (C-11) is a mouse monoclonal IgG1 κ, cited in 3 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 149-180 near the N-terminus of IGF2BP3 of human origin
- recommended for detection of IGF2BP3 of human origin by WB, IP, IF, IHC(P) and ELISA
- also available conjugated to Alexa Fluor® 790 for IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®/Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for IGF2BP3 Antibody (C-11) for WB and IHC(P) applications. These reagents are now offered in bundles with IGF2BP3 Antibody (C-11) (see ordering information below).
QUICK LINKS
SEE ALSO...
IGF2BP3 Antibody (C-11) is a mouse monoclonal IgG1 antibody that detects IGF2BP3 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). IGF2BP3, also known as insulin-like growth factor II mRNA-binding protein 3, plays a critical role in regulating mRNA stability and translation, which is essential for cellular growth and differentiation. IGF2BP3 is predominantly located in the cytoplasm, where IGF2BP3 binds to specific mRNAs, including those of IGF-II and c-Myc, thereby influencing their stability and translation efficiency. IGF2BP3′s localization is particularly important as IGF2BP3 allows for the fine-tuning of gene expression in response to cellular signals, which is crucial during processes such as embryonic development and tumorigenesis. Notably, IGF2BP3 has been implicated in various cancers, serving as a marker for carcinomas and high-grade dysplastic lesions of pancreatic ductal epithelium, highlighting IGF2BP3′s potential as a therapeutic target and a biomarker for cancer progression. With a unique ability to interact with multiple mRNAs and significant role in cancer biology, anti-IGF2BP3 antibody (C-11) is an invaluable tool for researchers studying mRNA regulation and its implications in disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IGF2BP3 Antibody (C-11) References:
- Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. | Mizutani, R., et al. 2016. Oncogene. 35: 3495-502. PMID: 26522719
- RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. | Palanichamy, JK., et al. 2016. J Clin Invest. 126: 1495-511. PMID: 26974154
- Prognostic Impact of IGF2BP3 Expression in Patients with Surgically Resected Lung Adenocarcinoma. | Guo, W., et al. 2021. DNA Cell Biol. 40: 316-331. PMID: 33493403
- LINC00460 facilitated tongue squamous cell carcinoma progression via the miR-320b/IGF2BP3 axis. | Wu, K., et al. 2022. Oral Dis. 28: 1496-1508. PMID: 33660359
- IGF2BP3‑stabilized SIX4 promotes the proliferation, migration, invasion and tube formation of ovarian cancer cells. | Han, J. and Hu, X. 2022. Mol Med Rep. 26: PMID: 35616130
- Knockdown of IGF2BP3 inhibits the tumorigenesis of gallbladder cancer and modifies tumor microenvironment. | Qin, Y., et al. 2022. Drug Dev Res. 83: 1831-1844. PMID: 36184877
- IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells. | Li, X., et al. 2022. Oncol Res. 30: 77-87. PMID: 37305324
- NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14. | Yang, ZY., et al. 2024. Cancer Lett. 587: 216703. PMID: 38341127
- m6A modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 contributes to angiogenesis of hepatocellular carcinoma. | Xu, X., et al. 2024. Mol Carcinog. 63: 2174-2189. PMID: 39092767
- IGF2BP3/CTCF Axis-Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas. | Sun, J., et al. 2024. Clin Respir J. 18: e70031. PMID: 39506204
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF2BP3 Antibody (C-11) | sc-365641 | 200 µg/ml | $322.00 | |||
IGF2BP3 Antibody (C-11): m-IgG Fc BP-HRP Bundle | sc-537819 | 200 µg Ab; 10 µg BP | $361.00 | |||
IGF2BP3 Antibody (C-11): m-IgGκ BP-HRP Bundle | sc-535229 | 200 µg Ab; 40 µg BP | $361.00 | |||
IGF2BP3 Antibody (C-11): m-IgG1 BP-HRP Bundle | sc-545375 | 200 µg Ab; 20 µg BP | $361.00 | |||
IGF2BP3 Antibody (C-11) Alexa Fluor® 790 | sc-365641 AF790 | 200 µg/ml | $364.00 | |||
IGF2BP3 (C-11) Neutralizing Peptide | sc-365641 P | 100 µg/0.5 ml | $69.00 |